About Us

Wuyan Pharmaceutical Technology (Shanghai) Co., Ltd.

Wuyan Pharmaceutical Technology (Shanghai) Co., Ltd. was founded in 2016. Located in the building 22, No.8666, Hunan Highway, Pu dong New District, Shanghai, P.R.China, our company is focusing on the customized synthetic drugs of complex small molecule skeleton, intermediates and APIs and takes it as the core development field. At the same time, we are also a provider of customized synthetic drugs production technical service for manufacturers. At present, our company is committed to the research, development and commercial production of intermediates and APIs with high technical barriers, high difficulty and high added values.


Adhering to the marketing concept of "customer first, sincere service", our company has successfully established in-depth cooperative relations with global partners to carry R&D and innovation projects from multiple fields of cooperation; therefore, we were rated as a high-tech enterprise and awarded the honorary title of "specialized-precise- special-new" Little Giant SME in Minhang District. In the future, our company will focus on the medication for public health crises and take international cGMP as the standard to continuously meet the various needs of global customers from starting materials, intermediates and APIs. We not only work hard to make our company an internationally competitive pharmaceutical R & D and production service enterprise, but also work hard to promote R & D innovation to improve the living conditions and quality of life of patients around the world.

Read More
2016
Incorporation
800 +
Global partners
5200 + m2
Place of business
3000 + m2
Laboratory

Main products

Lurbinectedin
CAT NO.: E7-C00 CAS NO.: 497871-47-3
Trabectedin
CAT NO.: E7-743 CAS NO.: 114899-77-3
Eribulin Mesilate
CAT NO.: ER01 CAS NO.: 441045-17-6
Exatecan mesylate
CAT NO.: WY052 CAS NO.: 169869-90-3
Eribulin
CAT NO.: S14 CAS NO.: 253128-41-5
Paxlovid
CAT NO.: WY10306 CAS NO.: 2628280-40-8
Lenacapavir
CAT NO.: WY207 CAS NO.: 2189684-44-2
Lenacapavir (GS-6207) Intermediate 3
CAT NO.: WY20731 CAS NO.: 1620056-83-8
Lenacapavir (GS-6207) Intermediate 2
CAT NO.: WY20708 CAS NO.: 2189684-54-4
Lenacapavir (GS-6207) Intermediate 1
CAT NO.: WY11405 CAS NO.: 2189684-53-3
Intermediate Corey 16
CAT NO.: E7-C16 CAS NO.: 265134-87-0
Corey 21
CAT NO.: E7-C21 CAS NO.: 182201-62-3
Eribulin Intermediate EB32
CAT NO.: EB32 CAS NO.: 481048-22-0
Eribulin Intermediate C2
CAT NO.: EC22 CAS NO.: 871348-24-2
Eribulin Intermediate B
CAT NO.: Eribulin Intermediate B CAS NO.: 157322-47-9
Eribulin Intermediate A
CAT NO.: EA14 CAS NO.: 157322-83-3
Eribulin Intermediate B+C2
CAT NO.: S5 CAS NO.: 253128-10-8
Indian customer on-site GMP audit
On April 29, 2023, an Indian customer came to the company for a quality audit of related products. The company's general manager and quality manager received customers from afar in the meeting ro...
Passed ISO9001:2015 quality system certification
From December 4th to 5th, 2022, the expert audit team of Intertek Certification Company conducted the first two-day audit of ISO9001:2015 quality system certification in the company. This audit c...
FDA approves a new drug for Biogen Alzheimer's disease, aducanumab
On June 7th, the US FDA announced approval for Bojian/Weicai Company Aβ (β Amyloid protein) antibody Aduhelm (aducanumab) Application for Biological Product License (BLA) for the treatment of ea...
Rongchang Biotechnology and Seattle Gene signed a contract: $2.6 billion! A New Record for Overseas Authorization of Vidiximab as a Single Drug
On August 8, 2021, Rongchang Biotechnology (09995. HK) reached a global exclusive licensing agreement with internationally renowned biopharmaceutical company Seagen Inc. (SGEN) to develop and com...
PerkinElmer acquires BioLegend, the leader of antibody and reagent
Waltham, Massachusetts - (BUSINESS WIRE) -; (American business information) -- PerkinElmer (New York Stock Exchange code: PKI) (“ PerkinElmer”) announced today that it has reached...
This is how cyclopeptides help cancer cells proliferate
Cyclic peptides help cancer cells proliferate. Cyclic peptides help cancer cells proliferate. Cyclic peptides help cancer cells proliferate. Cyclic peptides help cancer cells proliferate. Cyclic ...
Just now! Kangfang Biological/Zhengda Tianqing Anti PD-1 Monoclonal Antibody Approved for Market in China
On August 5th, the official website of the National Drug Administration (NMPA) of China announced that the anti PD-1 antibody drug, Paprilimab (AK105), jointly declared by Kangfang Biotechnology ...